Huntington's Disease Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Huntington's Disease Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Huntington's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Huntington's Disease Pipeline Report
• DelveInsight's Huntington's Disease pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Huntington's Disease treatment.
• The leading companies working in the Huntington's Disease Market include Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others.
• Promising Huntington's disease Pipeline therapies in the various stages of development include Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.
• April 2024: Sage Therapeutics announced a study of Phase 2 clinical trials for SAGE-718. The primary purpose of this study is to assess the magnitude of the baseline difference between participants with early Huntington's Disease (HD) and healthy participants (HP) with respect to measures of cognitive performance.
• April 2024: Vico Therapeutics B.V. announced a study of Phase 1 & 2 clinical trials for VO659. The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.

Request a sample and discover the recent advances in Huntington's Disease Treatment Drugs @ Huntington's Disease Pipeline Outlook Report- https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Huntington's Disease Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Huntington's Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Huntington's Disease Overview
Huntington's disease is a rare, inherited disease that causes the progressive breakdown (degeneration) of nerve cells in the brain. It is an autosomal dominant disorder caused by a single defective gene on chromosome 4. The symptoms of Huntington's Disease include involuntary jerking or writhing movements (chorea), muscle problems, such as rigidity or muscle contracture (dystonia), slow or abnormal eye movements, impaired balance, difficulty with speech or swallowing, difficulty organizing, prioritizing or focusing on tasks, and/or fatigue and loss of energy.

Find out more about Huntington's Disease Treatment Drugs @ Drugs for Huntington's Disease Treatment- https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Huntington's Disease Emerging Drugs Profile

• Pridopidine: Prilenia Therapeutics
Pridopidine is a highly selective, first in class small molecule which is sigma-1 receptor (S1R) agonist. Pridopidine is currently in late-stage clinical development for Huntington's disease. Prilenia has an orphan drug designation for pridopidine for the treatment of Huntington's disease in both the US and Europe.

• Tominersen: Ionis Pharmaceuticals
Tominersen (formerly known as IONIS-HTTRx and RG6042) is an investigational antisense medicine designed to reduce the production of the huntingtin (HTT) protein, which is the genetic cause of Huntington's disease (HD). The US FDA granted orphan drug designation to Ionis Pharmaceuticals, for tominersen for the treatment of Huntington's disease in January 2016. In August 2018, European Medicines Agency (EMA) granted PRIME (PRIority MEdicines) designation for the tominersen for the treatment of Huntington's disease (HD). Ionis Pharmaceuticals entered into a collaboration with Roche to develop and commercialize antisense medicines to treat HD in April 2013.

Huntington's Disease Therapeutics Assessment
There are approx. 50+ key Huntington's Disease companies which are developing the Huntington's Disease therapies. The Huntington's Disease companies which have their Huntington's Disease drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

DelveInsight's Huntington's Disease Pipeline Report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Huntington's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Huntington's Disease Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Huntington's Disease Pipeline Therapies @ Huntington's Disease Clinical Trials Assessment- https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Huntington's Disease Pipeline Report
• Coverage- Global
• Huntington's Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Huntington's Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Huntington's Disease Companies- Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, EIP Pharma, SAGE Therapeutics, Celon Pharma, PTC Therapeutics, WaVe life Sciences, Amsterdam Molecular Therapeutics, Novartis, Retrotope, Hope Biosciences, Stealth BioTherapeutics, Luye Pharma Group, Neurimmune Therapeutics, SOLA Biosciences, and others.
• Huntington's disease Pipeline therapies- Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others.

Dive deep into rich insights for new drugs for Huntington's Disease treatment, Visit @ Huntington's Disease Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Huntington's Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Huntington's Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Pridopidine: Prilenia Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Huntington's Disease Key Companies
21. Huntington's Disease Key Products
22. Huntington's Disease- Unmet Needs
23. Huntington's Disease- Market Drivers and Barriers
24. Huntington's Disease- Future Perspectives and Conclusion
25. Huntington's Disease Analyst Views
26. Appendix

For further information on the Huntington's Disease pipeline therapeutics, reach out to Huntington's Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/huntingtons-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.